Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Radioiodinated N-[3-(4-morpholino)propyl]-N-methyl-2-hydroxy-5-iodo-3-methylbenzylamine (ERC9): a new potential melanoma imaging agent
Autore:
Salopek, TG; Scott, JR; Joshua, AV; Smylie, M; Logus, JW; Morin, CA; McEwan, AJB;
Indirizzi:
Cross Canc Inst, Dept Oncol Imaging, Edmonton, AB T6G 1Z2, Canada Cross Canc Inst Edmonton AB Canada T6G 1Z2 , Edmonton, AB T6G 1Z2, Canada Cross Canc Inst, Dept Med, Edmonton, AB T6G 1Z2, Canada Cross Canc Inst Edmonton AB Canada T6G 1Z2 , Edmonton, AB T6G 1Z2, Canada Edmonton Radiopharmaceut Ctr, Edmonton, AB, Canada Edmonton Radiopharmaceut Ctr Edmonton AB Canada tr, Edmonton, AB, Canada Univ Alberta, Div Dermatol & Cutaneous Sci, Edmonton, AB T6G 2E1, Canada Univ Alberta Edmonton AB Canada T6G 2E1 Sci, Edmonton, AB T6G 2E1, Canada
Titolo Testata:
EUROPEAN JOURNAL OF NUCLEAR MEDICINE
fascicolo: 4, volume: 28, anno: 2001,
pagine: 408 - 417
SICI:
0340-6997(200104)28:4<408:RN>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON-EMISSION-TOMOGRAPHY; MALIGNANT-MELANOMA; METASTATIC MELANOMA; STAGE-I; F-18 FLUORODEOXYGLUCOSE; COST-EFFECTIVENESS; SURGICAL-TREATMENT; INITIAL ASSESSMENT; FOLLOW-UP; EXPERIENCE;
Keywords:
melanoma; radiopharmaceuticals; radionuclide imaging;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: McEwan, AJB Cross Canc Inst, Dept Oncol Imaging, 11560 Univ Ave, Edmonton,AB T6G 1Z2,Canada Cross Canc Inst 11560 Univ Ave Edmonton AB Canada T6G 1Z2 nada
Citazione:
T.G. Salopek et al., "Radioiodinated N-[3-(4-morpholino)propyl]-N-methyl-2-hydroxy-5-iodo-3-methylbenzylamine (ERC9): a new potential melanoma imaging agent", EUR J NUCL, 28(4), 2001, pp. 408-417

Abstract

The role of nuclear medicine in the management of patients with malignant melanoma has expanded in recent years with the introduction of lymphoscintigraphy and sentinel lymph node biopsy, intense interest in positron emission tomography (PET) imaging using 2-[F-18]fluoro-2-deoxyglucose (F-18-FDG) as a tracer, and encouraging reports of several new single-photon-emitting radiopharmaceuticals. While PET imaging with FDG exhibits a high sensitivityfor imaging patients with melanoma, specificity may not be as high and access to the technology remains limited. Single-photon emission tomography (SPET) imaging remains standard technology for most nuclear medicine departments. We report a novel radiopharmaceutical - radioiodinated N-[3-(4-morpholino) propyl]-N-methyl-2-hydroxy-5-iodo-3-methylbenzylamine (ERC9)-which appears to show a sensitivity and specificity that are commensurate with expectations of a radiopharmaceutical for routine clinical imaging. In this phase II trial, 110 patients at risk for recurrence, with suspected recurrence or being restaged have been imaged with this novel tracer, demonstrating anoverall sensitivity of 91% and specificity of 89%. The results of our study support a phase III trial to establish the clinical role of ERC9 in staging melanoma patients at presentation who are at high risk for metastasis, or restaging patients with known relapse to assess the extent of their disease, particularly if therapy or enrollment into a clinical trial is being considered.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 16:12:27